Inclusion of study participants
Forty-nine adult mastocytosis patients who were diagnosed according to
recent diagnosis and classification criteria(1) and
were followed at outpatient clinics of adult immunology and allergic
diseases and adult hematology divisions of our faculty were included in
the study . Accordingly, patients were grouped as follows; Group-1:
“Cutaneous Mastocytosis (CM)”, Group-2: “Indolent Systemic
Mastocytosis (ISM)” and Group-3: “Advanced Systemic Mastocytosis
(AdvSM) and Smoldering Systemic Mastocytosis (SSM)”. Aggressive SM
(ASM) and systemic mastocytosis (SM) with an associated hematologic
neoplasm (SM-AHN) were considered within the advSM group(1). Age, sex, body mass index and smoking habits
matched 25 healthy control (HCs) were also enrolled. Individuals with a
history of diabetes, hypertension, cancer, hyperlipidemia,
auto-inflammatory diseases, venous thromboembolism, atherosclerotic
diseases that can contribute to the development of endothelial
dysfunction and/or atherosclerosis were excluded. None of the study
participants were under ascorbic acid, corticosteroids, non-steroidal
anti-inflammatory drugs or estrogen therapy which can affect FMD
results.
This study was approved by the local institution’s ethics committee
(Approval Number:1293) in accordance with the Declaration of Helsinki
and written approval was received from all study participants .